Quarterly paliperidone injection for patients with schizophrenia

Trevicta (paliperidone palmitate) is a 3-monthly sustained-release injection for the maintenance treatment of schizophrenia. It can be given once patients are clinically stable on monthly paliperidone palmitate injection (Xeplion).

The extended dosing interval of Trevicta may help to reduce the risk of relapse caused by poor adherence to treatment.

Further information
View Trevicta drug record
Summary of Product Characteristics
Manufacturer: Janssen-Cilag

Trevicta is administered by intramuscular injection into the deltoid or gluteal muscle, with dose adjustments when required within the range of 175mg to 525mg.

Similar to other antipsychotics, the most common adverse effects experienced by patients given the quarterly paliperidone palmitate injection included insomnia, extrapyramidal effects, weight change, hyperglycaemia, urinary tract infection, upper respiratory tract infection and headache.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: fludroxycortide, levofloxacin, Noriday, Ongentys...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests